MARKET

HBIO

HBIO

Harvard Biosci
NASDAQ
2.270
-0.140
-5.81%
After Hours: 2.270 0 0.00% 16:01 11/28 EST
OPEN
2.370
PREV CLOSE
2.410
HIGH
2.420
LOW
2.220
VOLUME
65.32K
TURNOVER
0
52 WEEK HIGH
7.36
52 WEEK LOW
2.100
MARKET CAP
94.56M
P/E (TTM)
-13.5200
1D
5D
1M
3M
1Y
5Y
Keybanc Maintains Overweight on Harvard Bioscience, Lowers Price Target to $5
Benzinga · 11/09 09:50
--KeyBanc Capital Markets Trims Price Target on Harvard Bioscience to $5 From $7, Maintains Overweight Rating
--KeyBanc Capital Markets Trims Price Target on Harvard Bioscience to $5 From $7, Maintains Overweight Rating
MT Newswires · 11/09 09:47
Harvard Bioscience (HBIO) Reports Q3 Loss, Misses Revenue Estimates
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -120% and 3.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/08 23:05
Harvard Bioscience Non-GAAP EPS of -$0.01, revenue of $76.9M
Seekingalpha · 11/08 22:23
BRIEF-Harvard Bioscience Announces Third Quarter 2022 Financial Results
Reuters · 11/08 21:25
Harvard Bioscience Q3 EPS $(0.01) Misses $0.07 Estimate, Sales $26.92M Miss $28.89M Estimate
Benzinga · 11/08 21:03
-- Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q3 Revenue $26.9M, vs. Street Est of $28.7M
-- Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q3 Revenue $26.9M, vs. Street Est of $28.7M
MT Newswires · 11/08 16:19
-- Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q3 Loss $-0.01, vs. Street Est of $0.06
-- Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q3 Loss $-0.01, vs. Street Est of $0.06
MT Newswires · 11/08 16:15
More
About HBIO
Harvard Bioscience, Inc. is a developer, manufacturer, and seller of technologies, products and services that enable fundamental research, discovery, and preclinical testing for drug development. The Company provides products that support research in six different classes of laboratory use, including molecular, cellular, tissue, organ, organisms or preclinical, and clinical. The Company organizes its product line activities into two product families, Cellular and Molecular Technologies (CMT) and Preclinical. It primarily sells its products under several brand names, including Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. The Company's customers include pharmaceutical and biotechnology companies, as well as contract research organizations, academic labs, and government researchers.

Webull offers kinds of Harvard Bioscience, Inc. stock information, including NASDAQ:HBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HBIO stock methods without spending real money on the virtual paper trading platform.